3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neuroblastoma
20
Glioblastoma
4
Lung Neoplasms
3
Gliosarcoma
3
Glioma
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Oligodendroglioma
2
Neoplasms
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Kidney Neoplasms
2
Central Nervous System Neoplasms
2
Astrocytoma
2
Wilms Tumor
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Rhabdoid Tumor
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Pinealoma
1
Penile Neoplasms
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Second Primary
1
Neoplasms, Plasma Cell
1
Interventions
Filgrastim
10
Cyclophosphamide
8
Granulocyte Colony-Stimulating Factor
6
Melphalan
5
Busulfan
5
Vincristine
4
Topotecan
4
Temozolomide
4
Stem Cell Transplantation
4
Peripheral Blood Stem Cell Transplantation
4
Ifosfamide
4
Etoposide
4
Thiotepa
3
Radiotherapy
3
Mesna
3
Itraconazole
3
Doxorubicin
3
Cisplatin
3
Carboplatin
3
sargramostim
2
fludarabine
2
Therapeutics
2
Sirolimus
2
Radiotherapy, Intensity-Modulated
2
Nivolumab
2
Drug Therapy
2
Bone Marrow Transplantation
2
Blood Specimen Collection
2
Amplified Fragment Length Polymorphism Analysis
2
trioctyl phosphine oxide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Wilms Tumor
×
Isotretinoin
×
Clear all
NCT05384821
2026-03-18
MetroWilms
Centre Oscar Lambret
Phase 1/2
Recruiting
28 enrolled